Abstract
Introduction: The goal of this study was to elucidate a link of brain-derived factor (BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients.
 Methods: 256 post-myocardial infarction patients who underwent primary coronary intervention were enrolled in the study. Variants of Val66Met gene BDNF were identified by real-time chain reaction at baseline.
 Results: The combined clinical end points (major cardiovascular events and hospitalization) were determined in 61 (23.8%) post-STEMI patients; consequently, 195 (76.2%) patients did not meet the events. linear regression revealed that predictors for combined clinical end points were peak TnI levels, NT-proBNP, SYNTAX score, TIMI score, obesity, left ventricular ejection fraction, and 66ValMet+66MetMet in BDNF gene. The cumulative clinical outcomes (major adverse cardiac events and admission) were determined in 61 (23.8%) patients. Kaplan-Meier curves demonstrated that 66ValVal of BDNF gene was significantly associated with the low number of combined end points.
 Conclusion: The Val66Met in BDNF gene independently predicted 6-month combined clinical end points in post-myocardial infarction patients.
Highlights
The goal of this study was to elucidate a link of brain-derived neurotrophic factor (BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients
We did not find significant differences between both cohorts of the post-segment elevation myocardial infarction (STEMI) patients in terms of demographics, glomerular filtration rate, and CV risk factor presentation, except in the incidence of type 2 diabetes mellitus (DM) (T2DM) and hypertension, which were more frequently seen in patients who met major adverse cardiac events (MACEs) than in individuals who were free of MACEs (P = 0.032 and P = 0.0008, respectively)
We found that TIMI risk in patients with MACEs was significantly higher in comparison with individuals who had no combined endpoint (P = 0.046) (Table 2)
Summary
The goal of this study was to elucidate a link of brain-derived neurotrophic factor (BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients. Univariate linear regression revealed that predictors for combined clinical end points were peak TnI levels, NT-proBNP, SYNTAX score, TIMI score, obesity, left ventricular ejection fraction, and genotype 66ValMet+66MetMet in BDNF gene. Conclusion: The Val66Met polymorphism in BDNF gene independently predicted 6-month combined clinical end points in post-myocardial infarction patients. Recurrent major adverse cardiac events (MACEs) and heart failure (HF) remain the most common causes of premature cardiovascular (CV) mortality amid post-ST-segment elevation myocardial infarction (STEMI) patients, regardless of wide implementation of early re-vascularization strategies including primary percutaneous coronary intervention (PPCI) 1,2.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
